Key Takeaways
Extended Takeaways
- Endpoint status was a poor proxy for longitudinal course: among those classified as symptom persistent at study endpoint, 80.1% were actually fluctuating over time, and among endpoint remitters, 62.3% were fluctuating. A single adult follow-up visit may therefore misrepresent a patient's longer-term ADHD trajectory.
- Stable persistence was uncommon but clinically heavier, representing 10.8% of the sample and showing persistently high symptom burden with only ∼2–4 symptom difference between peaks and troughs, alongside relatively high and stable impairment, comorbidity, and substance use over time.
- Stable partial remission followed a different timeline than fluctuating ADHD, with the transition from ADHD to partial remission occurring in adulthood on average at mean = 18.87, SD = 5.81. Ongoing impairment and treatment use in this subgroup suggest that symptom improvement alone may not translate into functional recovery.
- Childhood baseline ADHD severity did not predict longitudinal course in this analysis, whereas parent SCID diagnoses, childhood mood disorder, childhood depression severity, and 36-month treatment response did. Prognostic assessment should therefore extend beyond symptom counts to family psychiatric burden and internalizing comorbidity.
- Within fluctuators, higher average environmental demands were linked to better concurrent status after adjusting for age: each added point was associated with a 1.58 higher odds of full remission versus persistence and a 1.36 higher odds of partial remission versus persistence. Patients who function well with greater responsibility may not fit the assumption that lower demands are always protective.
- The time-varying demands signal was age-sensitive: for each point above a person's own average environmental demands, fluctuators were 1.28 times more likely to be in full remission versus persistence, but this association weakened as individuals progressed through adulthood. Environmental fit may therefore be most informative for symptom monitoring and care planning earlier in development.
